Protein Expression Market Worth $3.0 Billion By 2025

The global protein expression market is expected to reach USD 3.0 billion by the year 2025 growing at a CAGR of 10.4%, according to a new report by Grand View Research, Inc. The growing demand for biologics and expansion of the biopharmaceutical industry have resulted in massive growth of the protein expression market. Rising demand for therapeutic proteins such as insulin, hormones, monoclonal antibodies, and vaccines is a major factor that propels growth of the market during forecast period. Thus, many biotechnology and pharmaceuticals companies have begun to concentrate on the development and manufacturing of advanced therapeutic proteins for the treatment of severe chronic diseases such as cancer, hemophilia, infectious diseases, anemia, and multiple sclerosis.

Increasing investment in the R&D, by biotechnology and pharmaceutical companies, is another major factor supporting the sector growth. The availability of new and advanced technologies to cater the needs of drugs & biologics product manufacturers boosts the adoption of protein expression products for research and manufacturing applications. In addition, several pharmaceutical and biotechnology manufacturers are undergoing collaborations and partnerships to achieve leadership in the sector. For instance, in December 2016, Takara Bio, Inc. signed a merger agreement with Rubicon Genomics, Inc. to strengthen its genomics business.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/protein-expression-market

Further Key Findings From The Report Suggest:

Prokaryotic expression systems segment was the largest revenue-generating amongst others owing to its large application in biologics and drug productions
Mammalian cell expression systems is the fastest growing segment of the protein expression market owing to its growing demand for proteomics research and biologics manufacturing
Reagents segment held the largest revenue share in the market, which is attributed to its repetitive purchase for therapeutic, industrial, and research applications
The services segment is projected to grow at highest rate due to increasing trend of outsourcing of protein expression services by research labs and drug manufacturers
Therapeutic application segment was leading in 2016, due to high demand of therapeutic proteins for the treatment of cancer, infectious diseases, anemia, hemophilia, and multiple sclerosis
The pharmaceutical and biotechnological companies segment dominated the sector in terms of revenue in 2016 due to rising focus on proteomics research and increasing production of biologics products
North America was the leading regional market in 2016 and is expected to maintain its dominance during the forecast period, because of the presence of large number of biopharmaceutical and biotechnology companies in this region
The Asia Pacific region is projected to grow at a highest CAGR during the forecast period owing to untapped opportunities in the developing countries including China and India
Some of the major players include Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Merck KGaA, New England Biolabs, Promega Corporation, Qiagen, and Takara Bio, Inc.

Molecular Diagnostics Market Worth $18.2 Billion By 2027

The global molecular diagnostics market size is expected to reach USD 18.2 billion by 2027, according to a new report by Grand View Research, Inc., registering a CAGR of 9.0% over the forecast period. Increasing prevalence of infectious diseases such as influenza and human papillomavirus is projected to be the key factor the growth of the market.

In the underdeveloped regions of Africa, increasing instances of infections such as tuberculosis and HIV have been witnessed in the last few years. This is projected to drive the demand for accurate and early diagnostic techniques to curb the spread of these infections.

Rapid technological advancements-leading to accurate results, portability, and cost-effectiveness-are expected to be a high impact rendering driver for this market. Companies are upgrading their products by implementing new techniques to gain specific and accurate results. Companies such as Sigma Aldrich Corporation and Qiagen are developing a new range of molecular diagnostic techniques, such as Transcription-Mediated Amplification (TMA) and Loop-Mediated Isothermal Amplification (LAMP), for the diagnosis of tumors.

Key players in the market are adopting various marketing strategies such as collaborations with technologically advanced companies and diagnostic centers. Furthermore, players are focusing on expanding their geographic presence in order to increase their market share.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/molecular-diagnostics-market

Further key findings from the report suggest:

Reagents dominated the market in 2019 and is also projected to be the fastest-growing product segment owing to its high adoption in research and clinical settings. Standard reagents also provide efficient and accurate results
Instruments such as next generation sequencing platforms and PCR are increasingly preferred by diagnostic institutes and central laboratories as these tests deliver reliable and quick results and are suitable for a number of diagnostic procedures
Central laboratories emerged as the leading test location for molecular diagnostics in 2019. This is attributed to the availability of skilled labor and well-established infrastructure
Point-of-care is expected to be the fastest-growing segment over the forecast period owing to increase in demand for bedside testing, accuracy of results, and rise in healthcare awareness
Infectious diseases were the largest revenue generating segment in 2019 as molecular diagnostics offer clinicians with better substitutes to diagnose numerous infectious pathogens, bacteria, and virus in a short time while producing extremely accurate results
The oncology segment is projected to exhibit a CAGR of around 11.3% over the forecast period owing to increasing awareness amongst patients and healthcare professionals regarding available technologies such as molecular testing for cancer diagnosis
On the basis of technology, PCR was the largest revenue generating segment in 2019 owing to factors such as growing applications of multiplex PCR and commercialization of easy-to-use PCR-based molecular diagnostic kits
North America was the largest revenue generating region in 2019, followed by Europe. Key factors attributing to their dominance are high patient awareness levels, sophisticated healthcare infrastructure, growing healthcare expenditure, and high R&D pertaining to drug discovery and development
Some of the major players operating in molecular diagnostics market are F. Hoffmann-La Roche Ltd; Siemens Healthcare GmbH; Bio-Rad Laboratories, Inc.; Novartis AG (Grifols); Danaher Corporation; Alere, Inc.; Sysmex Corporation; bioMérieux SA; Becton, Dickinson and Company; Hologic, Inc. (Gen Probe); Johnson & Johnson Services, Inc.; Bayer AG; Cepheid; Dako; and Qiagen.

Molecular Diagnostics Market Worth $18.2 Billion By 2027

Click the link below:
https://www.grandviewresearch.com/industry-analysis/molecular-diagnostics-market

Further key findings from the study suggest:

Reagents dominated the market in 2019 and is also projected to be the fastest-growing product segment owing to its high adoption in research and clinical settings. Standard reagents also provide efficient and accurate results
Instruments such as next generation sequencing platforms and PCR are increasingly preferred by diagnostic institutes and central laboratories as these tests deliver reliable and quick results and are suitable for a number of diagnostic procedures
Central laboratories emerged as the leading test location for molecular diagnostics in 2019. This is attributed to the availability of skilled labor and well-established infrastructure
Point-of-care is expected to be the fastest-growing segment over the forecast period owing to increase in demand for bedside testing, accuracy of results, and rise in healthcare awareness
Infectious diseases were the largest revenue generating segment in 2019 as molecular diagnostics offer clinicians with better substitutes to diagnose numerous infectious pathogens, bacteria, and virus in a short time while producing extremely accurate results
The oncology segment is projected to exhibit a CAGR of around 11.3% over the forecast period owing to increasing awareness amongst patients and healthcare professionals regarding available technologies such as molecular testing for cancer diagnosis
On the basis of technology, PCR was the largest revenue generating segment in 2019 owing to factors such as growing applications of multiplex PCR and commercialization of easy-to-use PCR-based molecular diagnostic kits
North America was the largest revenue generating region in 2019, followed by Europe. Key factors attributing to their dominance are high patient awareness levels, sophisticated healthcare infrastructure, growing healthcare expenditure, and high R&D pertaining to drug discovery and development
Some of the major players operating in molecular diagnostics market are F. Hoffmann-La Roche Ltd; Siemens Healthcare GmbH; Bio-Rad Laboratories, Inc.; Novartis AG (Grifols); Danaher Corporation; Alere, Inc.; Sysmex Corporation; bioMérieux SA; Becton, Dickinson and Company; Hologic, Inc. (Gen Probe); Johnson & Johnson Services, Inc.; Bayer AG; Cepheid; Dako; and Qiagen.

Apoptosis Assay Market Size Worth $7.5 Billion By 2027

The global apoptosis assay market size is expected to reach USD 7.5 billion by 2027, expanding at a CAGR of 7.6%, according to a new report by Grand View Research, Inc. Extensive research activities on expanding applications of drug-induced apoptosis assays have propelled the inclination of pharmaceutical manufacturers towards incorporating cell cycle products in the drug discovery and designing process.

The introduction of affordable and easy to perform kits that can be accommodated in complex experiments is expected to minimize the overhead costs of apoptosis experiments. Companies are providing highly precise reagents and lot-to-lot reproducibility in sample measurements.

Professionals at pharmaceutical companies are making use of cell-cycle inhibitors and Apoptosis-Inducing Factors (AIF)/ molecules to explore possible drug targets. Also, high demand for caspase activity assays along with Bcl-2 protein family across pharmaceutical companies for apoptosis detection has been observed in recent years. Biotechnology companies are enhancing quantification techniques to enable real-time monitoring of apoptotic cellular dynamics.

The presence of established guidelines and protocols for cell-potency assays has strengthened the development of efficient cell-death detection assays. Whereas, stringent regulations with respect to the approval of cell-potency assays are ensuring successful uptake of market products launched.

The flow cytometry segment dominated the market and accounted for the largest revenue share in 2019. This is attributed to the increasing adoption of the technique among researchers. It helps in finding the difference between intact mitochondria (healthy cells) and permeabilized mitochondria (cells undergoing death). The segment is anticipated to grow fast over the forecast period.

The pharmaceutical and biotechnology segment dominated the market in 2019 and is anticipated to continue its dominance over the forecast period. This is attributed to the rising incidence of cancer and neurodegenerative disorders. In addition, the growing significance of programmed cell death or apoptosis to treat chronic diseases is driving the segment growth.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/apoptosis-market

Further key findings from the study suggest:

The kits segment dominated the market and accounted for a revenue share of around 50.0% owing to increasing investment by key market players
Increase in the demand for fluorochrome-labeled inhibitors of caspases has made reagents the fastest growing product segment in the market
Application of these inhibitors with other techniques is anticipated to enhance the apoptosis assessment, thereby driving segment growth
Owing to the wide adoption and easy availability of products, flow cytometry is estimated to account for a substantial share of approximately 35.0% in 2019
The increasing significance of continuous monitoring of programmed cell death across novel drug discoveries and development of advanced therapeutics is set to propel market growth
North America has dominated the market in terms of revenue share in 2019, and Asia Pacific is expected to witness the fastest growth in the coming years as a result of the expanding CRO landscape in the region
Key companies are competing in terms of a combination of products and services in order to maintain market share.

Latin America In Vitro Diagnostics Market Size To Reach $5.1 Billion By 2024

The latin america IVD market is expected to reach over USD 5.1 billion by 2024, according to a new report by Grand View Research, Inc. The Latin America IVD market is expected to grow at a significant CAGR till 2024 owing to the rising prevalence of target disorders, aging population, and the presence of favorable government initiatives for early disease diagnosis. Other factors that are anticipated to boost the growth include the introduction of technologically advanced instruments and the increasing R&D initiatives for the development of disease-specific kits.

Regular testing for diabetes, cardiovascular, cancer, and sexually transmitted diseases are necessary for the timely treatments, further avoiding the risk of fatal health complications. The availability of tests for home and near patient testing is estimated to further enhance the usage rates of these devices. From November 2015, the Anvisa, which is a regulatory body for medical devices in Brazil, has started allowing the registration for HIV self-testing kits.

The increasing adoption point of care devices coupled with the increasing awareness among the healthcare professionals regarding the early diagnosis of various diseases has provided a boost to the Latin IVD market. The rising epidemic of communicable diseases in the southernpart of Latin America, the growing need for rapid and accurate diagnostics, and the changing healthcare infrastructure scenario are some of the key drivers of the Latin IVD market.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/latin-america-in-vitro-diagnostics-ivd-market

Further key findings from the study suggest:

The instrument segment is one of the most important segments of in vitro diagnostics. The presence of highly automated analyzers and the availability of over the counter products are some of the factors responsible for its significant share.
The Molecular diagnostics segment is anticipated to be the fastest growing technology over the decade. Molecular diagnostics is a transformative area of diagnostics. The continuous innovation in technology helps the physicians for critical decision making
The infectious disease segment held the largest share in 2015 over 24% owing to the presence of favorable government initiatives in association with the WHO to curb communicable diseases.
The home care segment is estimated to witness a significant growth over the forecast period. The high number of R&D initiatives undertaken by key competitors for the development of portable IVD devices with improved sensitivity and user-friendliness is a key factor attributing towards its growth.
In 2015, Brazil was the largest regional segment with a revenue generation of over USD 1.2 billion owing to the established healthcare infrastructure, growing awareness for cancer screening, and the increasing demand for genetic testing.
Peru is expected to be one of the fastest growing regions on account of the growing economic stability, high unmet clinical needs, and the rising disposable incomes
Key players operating in the Latin America IVD market are Roche Diagnostics, Abbott Laboratories, Inc., Hologic (Gen-Probe), Becton Dickinson (BD) Company, Alere, Inc., Bio-Rad Laboratories, Qiagen N.V., Inc., bioMerieux, BioQuidel Corporation, and Siemens Healthcare.

Protein Labeling Market Size Worth $2.60 Billion By 2024

The global protein labeling market size is expected to reach USD 2.60 billion by 2024, according to a new report by Grand View Research, Inc., registering a CAGR of 9.3% during the forecast period. Development and commercial launch of high accuracy and rapid labeling products is expected to enhance market growth.

Post-translation Modification (PTM) such as proteolysis, lipidation, acetylation, methylation, nitrosylation, ubiquitination, glycosylation, and phosphorylation influence all aspects of pathogenesis as well as normal cell functioning. PTM studies are rapidly being adopted to investigate biological functions of various proteins and their role in disease prognosis.

Availability of a broad range of labels for covalent attachment of different molecules provides researchers the choice to select labels to suit specific applications. Fluorescent labeling does not require additional reagents for protein detection due to its ability to respond to light signals. This ability of fluorescence molecules has significantly contributed to its rapid adoption in in vivo protein labeling.

High R&D spending to reduce complexity in protein labeling and increased adoption of sophisticated bioengineering techniques in various sectors of biotechnology further contribute to market growth. Development of rapid diagnostic tests based on detection of the presence of specific protein proves to be of great significance for rapid and cost-effective diagnostics. Focus on development of advanced diagnostic tests based on protein detection is expected to fuel new product development.

Technological advancements in genetic sequencing methodologies has drastically reduced the cost of genome profiling. This is expected to drive demand for protein expression analysis, which is the next step in genetic analysis after sequencing. Declining sequencing cost has increased the number of proteomic and genomic profiling studies, which is projected to fuel demand for protein labeling over the forecast period.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/protein-labeling-market

Further key findings from the report suggest:

Rapid adoption of post-translational modification studies in proteomics is expected to fuel demand for reagents
SNAP-, CLIP-, MCP-, and ACP- tags are some of the fusion proteins used for covalent labeling. Ability to provide irreversible covalent labeling and labeling for membrane protein drives demand for probes/tags in labeling
Demand for kits for clinical diagnosis of various diseases based on protein detection fuels the kits product segment
North America dominated the market due to presence of key players and high investments in proteomics research. Canada is poised to witness lucrative growth owing to increasing number of research projects focused on improving healthcare solutions
Europe is a key regional market. The Seventh Framework Program of the European Union provided funds for P-CUBE – an infrastructure for Protein Production Platforms to provide access to most advanced techniques to researchers
Asia Pacific is expected to observe remarkable growth over the forecast period, especially in China and Japan
Major companies operating in the market include F. Hoffmann-La Roche AG; GE Healthcare Life Science; Promega Corporation; PerkinElmer Inc.; Merck Millipore; Thermo Fisher Scientific Inc.; Kirkegaard & Perry Laboratories (KPL); Eurogentec S.A.; New England Biolabs; and LI-COR Inc.
Key players are involved in acquisition of smaller players and are expanding their product portfolio, resulting in market consolidation.

High Resolution Melting Analysis Market Worth $131.7 Million By 2022

Global High Resolution Melting (HRM) market is expected to reach USD 131.7 billion by 2022 according to a new report by Grand View Research Inc.

Increasing incidences of cancer, sickle cell anemia, HIV and other STDs are expected to positively reinforce demand for smart and simple molecular diagnostics. According to the Genetic and Rare Diseases Center (GARD) in 2014, 10% of the U.S. population that is nearly 30 million people were suffering from genetic disorders. Some key disease statistics are reported below:

As per the estimates provided by CDC, number of acute cases of hepatitis C reported in the United States increased from 1,778 to 2,138 from 2012 to2013
According to the UNAIDS report, out of the 36.9 million people that are suffering with HIV/AIDS, 17.1 million are unaware about disease occurrence due to unavailability of testing services
As per the WHO estimates in 2015, there are over 130-150 million people suffering with HCV globally

Based on analyzing the disease trends and relatively lower treatment rates suggests that the demand for gene mutation and other genomic tests are expected to increase significantly over the next few years. Recent developments in the field of QPCR, next generation sequencing, genomics and big data analytics have been instrumental in strengthening the precision medicine approach. The U.S. FDA has already approved some of the treatments which are designed to meet the requirements of a specific genetic makeup or the genomic profile of the patient’s tumor.

For instance, the U.S FDA has approved a new treatment for cystic fibrosis (CF) in January, 2012. The drug kalydeco was approved for patients reported to have a specific genetic mutation known as “G551D mutation. The number of mutations which can lead to CF is in hundreds, and the G551D mutation is responsible for nearly 4% of the cases in the U.S.

Furthermore, in 2015, the Obama administration has announced the Precision Medicine Initiative with an investment of USD 216 million in the 2016 president’s budget. This initiative is expected to positively reinforce the HRM analysis market over the forecast period.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/high-resolution-melting-analysis-market

Further key findings from the study suggest:

In 2014, North America dominated the overall HRM analysis market with a share of nearly 42%. Key factors attributed are high disease prevalence rates, presence of large number of academic universities; strong pharmaceutical and biotech industry, presence of large number genetic testing centers, and rapid adoption of novel technologies for improving the healthcare outcomes.
Asia pacific is identified as the fastest growing region over the forecast period. Key reasons attributed are increasing public and private expenditure on molecular diagnostics and genetic testing, increasing prevalence of genetic disorders, and increasing burden of chronic diseases such as cancer, COPD, HIV and others.
Key market players in the High Resolution Melting analysis market include, Roche Molecular Systems, Idaho Technology Corporation, Kapa Biosystems, Thermo Fisher Scientific, Premier Biosoft and Qiagen. Furthermore, Roche Molecular Systems leads the industry with the highest R&D expenditure and commands a significant market share.

Epigenetics Market Size Worth $22.05 Billion By 2025

The global epigenetics market size is expected to reach USD 22.05 billion by 2025, according to a new study by Grand View Research, Inc., progressing at a CAGR of 19.7% during the forecast period. The growing prevalence of cancer and other diseases worldwide with an epigenetic modification base is expected to drive the market during the forecast period.

Diagnostic companies are coming up with new products such as antibodies specific for the detection of modifications and new upgraded kits for easy and efficient detection of biomarkers. This is estimated to attract pharmaceutical companies to collaborate for the development of therapeutic drugs, which will work in favor of the market.

The presence of pipeline drugs and their expected commercialization is anticipated to boost the growth of the market. For instance, Ramucirumab (Cyramza) by Eli Lilly and Company was approved by the FDA for use in combination with Folfiri for the treatment of patients with metastatic colorectal cancer.

Technology advancements in the epigenetics industry are majorly focusing on the detection of methylation markers related to cancer development. For instance, Epi proLung BL Reflex Assay by Epigenomics helps in the diagnosis of lung cancer by determining methylation of SHOX2 biomarker gene.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/epigenetics-market

Further key findings from the study suggest:

On the basis of product, reagents held the largest share in the market in 2017. They are projected to amount to approximately USD 7.06 billion by 2025 owing to increasing R&D activities in the field of epigenetics
The kits segment is expected to post a CAGR of over 20.0% due to the need for rapid and accurate detection techniques
DNA methylation, on the basis of technology, held the leading revenue share in the market in 2017, accounting for just over 47.0%. The rapid adoption of advanced techniques such as methylation-sensitive PCR (MSP) to improve diagnostics efficiency is poised to bolster the growth of the segment
North America commanded the leading position in the global arena with a share of 40.0% in 2017. The growth of the regional market can be attributed to the increasing prevalence of cancer and growing collaborations between large pharmaceutical firms for the development of improved therapeutics
Asia Pacific is estimated to register a noteworthy CAGR of 22.1% during the forecast period owing to the presence of a large target population coupled with high unmet clinical needs
Some of the major players of epigenetics market are Illumina; Abcam; Diagenode; Thermo Fisher Scientific; Merck; Zymo research; Qiagen; CellCentric Ltd; Chroma Therapeutics Ltd; Eisai Co. Ltd; Novartis International AG; Oncolys Biopharma Inc.; Syndax Pharmaceuticals, Inc.; Valirx Plc; and Sigma-Aldrich Corporation
Extensive R&D initiatives for the development of novel drugs and the presence of strong product pipeline are expected to further boost market growth over the forecast period.